Project Grant R01CA312208
Award Date 6/18/26
Completion Date 5/31/31
Dollars Obligated $561K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $149,190 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective December 18, 2025, with a completion date of September 19, 2027. This award supports research training and career development initiatives in cancer research aligned with the National Cancer Program's strategic priorities. The funding enables the institution to provide biomedical...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $885,632 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) beginning April 2, 2026, with a completion date of March 31, 2028. This research project focuses on interrogating the erythroid differentiation and BCL-XL (B-cell lymphoma-extra large) axis in TP53-mutated acute myeloid leukemia (AML). The research aims to develop and evaluate novel therapeutic...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on May 1, 2026, with completion targeted for April 30, 2031. The award supports research into synthetic-lethal cancer therapy approaches targeting methylthioadenosine phosphorylase (MTAP)-deleted and MTAP-proficient tumors. The research deliverables include development and characterization of highly...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary New York University School of Medicine received a $716,681 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 22, 2026, with completion targeted for April 30, 2031. This award supports fundamental research aimed at understanding the cause, nature, and mechanisms of myeloid sarcoma (MS), a rare subtype of acute myeloid leukemia (AML) affecting approximately 5-10% of AML patients....
- Federal Grant Award Summary Albert Einstein College of Medicine received a $680,121 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. The award supports fundamental research aimed at understanding immunoevasion mechanisms in basal-like breast cancer (BLBC) precancer stem cells to develop immunoprevention strategies for cancer interception. The research focuses on elucidating how...
- Federal Grant Award Summary The National Cancer Institute awarded a $444,590 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, with completion targeted for May 31, 2028. The project focuses on evaluating genetic and epigenetic determinants of treatment response in patients with accelerated and blast phase myeloproliferative neoplasms (MPNs), rare blood cancers with poor prognosis and limited effective...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $431,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Albert Einstein College of Medicine, effective April 1, 2026, through March 31, 2028. This award funds research to investigate dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining CD123-directed natural killer (NK) cell engagement with BCL-2 inhibition. The research examines the efficacy and molecular...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $168,000 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded April 1, 2026, with completion scheduled for March 31, 2028. This research initiative focuses on understanding and targeting dormancy mechanisms in pancreatic ductal adenocarcinoma (PDAC) to improve patient survival outcomes. The project investigates minimal residual dormant disease (MRD)...
- Federal Grant Award Summary The National Cancer Institute awarded Albert Einstein College of Medicine a $431,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2028. This award supports research to decipher the mechanisms of resistance to anti-TROP2 cancer therapy using novel humanized mouse models. The project addresses a critical clinical limitation: while sacituzumab govitecan (SG), an anti-TROP2 antibody-drug conjugate...